ARES vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARES exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating solid profitability and operational efficiency. However, the stock trades at a significant premium to both Graham's defensive value ($26.55) and intrinsic value ($67.56), currently priced at $155.89, reflecting high growth expectations. While revenue and earnings growth are robust—46.7% and 108.8% YoY respectively—the elevated valuation metrics (P/E of 68.07, P/B of 11.40) and bearish insider activity raise sustainability concerns. The technical trend is bearish, and the dividend payout ratio of 181% signals potential instability in income sustainability.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
ARES vs JPM: Head-to-Head Comparison
This page compares Ares Management Corporation (ARES) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.